Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar, bevacizumab) in Russia

Shots:

• Pharmapark to get exclusive rights to commercialize HD204 and is responsible for local registration, sales, and marketing of the biosimilar in Russia in collaboration with Russian import substitution strategy
• Prestige BioPharma will be responsible for commercial supply the product out of its manufacturing facilities in Osong, Korea
• Prestige’s (HD204) is currently being evaluated in P-III SAMSON-II trial that involves assessing the safety & efficacy of HD204 to the reference, Roche’s Avastin for multiple cancer indications

Click here to­ read full press release/ article | Ref: Business Wire | Image: CPhl Online